Pharmanutra (PHN) Q1 2026 earnings summary

Executive summary

• Revenues for Q1 2026 rose 24.5% year-over-year to €33.4 million, driven by strong growth in both domestic and international markets and supported by strategic investments.

• Net profit increased 41.9% to €3.5 million, with EPS up 42.2% to €0.36.

• EBITDA rose 25.8% to €6.2 million, representing 18.6% of revenues.

• Sales volumes grew 22% to 3.7 million units.

• New business units, especially in the USA and China, contributed €2.3 million, up 108% year-over-year.

Financial highlights

• Net revenues reached €33.4 million, up from €26.4 million in Q1 2025.

• EBITDA margin was 18.6% (26% excluding new business units).

• Net financial position was positive at €11.9 million, up from €11.4 million at year-end 2025.

• Cash and cash equivalents increased to €21.2 million from €18.6 million at year-end.

• Cash generated by operating activities totaled €1.9 million.

Segment performance

• Italian market revenues grew 14.8% to €19.8 million (60.7% of total), while foreign market revenues surged 41.5% to €12.9 million (39.3% of total).

• Akern/medical instruments segment contributed €2.3 million (+11%), mainly in Italy.

• Sideral® products accounted for 95% of foreign sales and grew 28.9%; Cetilar® up 20.6%, Apportal® up 19.7%.

• Notable geographic growth in North America (+323.5%), Far East (+74.6%), and South America (+94.5%).

• New business units contributed €2.3 million (+108%), with ROW New BU revenues up 143%.